Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943084 · ClinicalTrials.gov registry record · Phase 1
A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01943084 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 32 participants.
The verdict
NCT01943084, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the bioequivalence (the expected biological equivalence of two pharmaceutical drug products with identical active ingredient) of Norditropin® (somatropin) versus Genotropin® (somatropin) in healthy adult subjects.
Interventions
- DRUG Norditropin® FlexPro® pen
- DRUG Genotropin Pen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943084
The ClinicalTrials.gov registry entry for NCT01943084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Norditropin® FlexPro® pen is the first listed.
NCT01943084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943084 about?
NCT01943084 is a clinical study titled "A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects". This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the bioequivalence (the expected biological equivalence of two pharmaceutical drug products with identical active ingredient) of Norditropin® (somatropin) versus Genotropin® (somatropin) in healthy ...
What is the current status of trial NCT01943084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01943084?
The interventions under investigation include: Norditropin® FlexPro® pen (DRUG), Genotropin Pen® (DRUG).
Who is sponsoring clinical trial NCT01943084?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.